Pediatric pulmonology · 2025
Newborn Screening for Cystic Fibrosis Is Associated With the Lowest Healthcare Costs: A 10-Year Observational Follow-Up Study in France.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guyot Erika, Deygas Floriane, Belhassen Manon, Berard Marjorie, Van Ganse Eric, Sermet-Gaudelus Isabelle, Tiaiba Sabrine, Dubus Jean-Christophe, Durieu Isabelle, Reix Philippe
Аннотация
OBJECTIVES: This study aims to study the healthcare (HC) costs associated with cystic fibrosis (CF) in children diagnosed prenatally (ANT), through newborn screening (NBS), after birth due to meconium ileus (MI), or later based on symptoms (LS). Additionally, it seeks to clinically characterize children with CF (chCF) with different trajectories of HC costs.
STUDY DESIGN: A retrospective observational study was conducted on data from the French CF Registry (FCFR) and the French National Claims Database (SNDS) linked from 2006 to 2021. HC costs related to CF diagnosis circumstances were estimated per year of life among chCF up to age 10. Group-based trajectory modeling was performed to identify subgroups with similar cost trajectories.
RESULTS: Between 2006 and 2011, data from 1065 chCF were recorded in the FCFR. Nine hundred seventy-three (91.4%) were matched with SNDS, and 779 (73.1%) had at least 10 years of follow-up. During the first year, HC costs of chCF diagnosed with NBS were lower than for those diagnosed with MI and ANT (all p < 0.05). However, by the tenth year HC were no longer different between groups. Three groups with different cost trajectories were identified. Groups with the highest costs had a lower lung function at 6 and 10 years and the lowest weight and height z-scores at 2 and 10 years (all p < 0.05).
CONCLUSION: NBS is associated with the lowest HC costs during the first year of life.
STUDY DESIGN: A retrospective observational study was conducted on data from the French CF Registry (FCFR) and the French National Claims Database (SNDS) linked from 2006 to 2021. HC costs related to CF diagnosis circumstances were estimated per year of life among chCF up to age 10. Group-based trajectory modeling was performed to identify subgroups with similar cost trajectories.
RESULTS: Between 2006 and 2011, data from 1065 chCF were recorded in the FCFR. Nine hundred seventy-three (91.4%) were matched with SNDS, and 779 (73.1%) had at least 10 years of follow-up. During the first year, HC costs of chCF diagnosed with NBS were lower than for those diagnosed with MI and ANT (all p < 0.05). However, by the tenth year HC were no longer different between groups. Three groups with different cost trajectories were identified. Groups with the highest costs had a lower lung function at 6 and 10 years and the lowest weight and height z-scores at 2 and 10 years (all p < 0.05).
CONCLUSION: NBS is associated with the lowest HC costs during the first year of life.